Bristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow BMY
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Net Income |
9,274.00 | 7,271.00 | 7,055.00 | 6,046.00 |
+8 more TTM periods Free account |
Depreciation & Amortization |
3,176.00 | 3,593.00 | 4,011.00 | 4,914.00 | |
Non Cash Items (Other) |
2,389.00 | 3,844.00 | 3,545.00 | 3,186.00 | |
Accounts Receivable Change |
678.00 | 1,377.00 | (295.00) | (171.00) | |
Change in inventories |
(41.00) | (1.00) | (184.00) | (80.00) | |
Change in payables and accrued liability |
450.00 | 492.00 | (2.00) | 605.00 | |
Income tax paid |
228.00 | 129.00 | (4.00) | 441.00 | |
Change in other assets and liabilities |
(3,372.00) | (3,415.00) | 30.00 | 1,680.00 | |
Other operating activities |
— | 53.00 | — | — | |
Operating Cash Flow |
12,782.00 | 13,306.00 | 14,156.00 | 16,621.00 | |
Capital expenditures |
(1,342.00) | (1,398.00) | (1,311.00) | (1,319.00) | |
Net Aquisitions |
(2,658.00) | (2,791.00) | (2,873.00) | (1,159.00) | |
Short Term Investments Change (Net) |
(1,399.00) | (31.00) | (25.00) | (658.00) | |
Long-Term Investments Change (Net) |
494.00 | 456.00 | 77.00 | 266.00 | |
Investing cash flow |
(4,905.00) | (3,764.00) | (4,132.00) | (2,870.00) | |
Repayment/Issuance of Debt (Net) |
(6,487.00) | (5,722.00) | (5,175.00) | (846.00) | |
Equity Repurchase (Common, Net) |
(83.00) | (193.00) | — | (79.00) | |
Dividends Paid (Total) |
(5,095.00) | (5,070.00) | (5,045.00) | (5,001.00) | |
Other financial activities |
— | — | (41.00) | — | |
Financing cash flow |
(11,709.00) | (10,915.00) | (10,348.00) | (5,961.00) | |
Exchange Rate Adjustment |
(57.00) | 81.00 | 195.00 | 43.00 | |
Change in Cash |
(3,889.00) | (1,292.00) | (129.00) | 7,833.00 | |
Beginning Cash |
10,218.00 | 10,218.00 | 10,347.00 | 10,347.00 | |
Ending Cash |
6,329.00 | 8,926.00 | 10,218.00 | 18,180.00 | |
Stock Based Compensation |
553.00 | 555.00 | 553.00 | 540.00 | |
Dividends Paid (Common) |
(5,095.00) | (5,070.00) | (5,045.00) | (5,001.00) | |
Assets Liabilities Change (Total) |
(2,057.00) | (1,418.00) | (455.00) | 2,475.00 | |
Investments Change (Net) |
(905.00) | 425.00 | 52.00 | (392.00) | |
Issuance/Purchase of Shares |
(83.00) | (193.00) | — | (79.00) |